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BACKGROUND
Androgen-deprivation therapy (ADT) has been the backbone of treatment for 
metastatic prostate cancer since the 1940s. We assessed whether concomitant 
treatment with ADT plus docetaxel would result in longer overall survival than that 
with ADT alone.
METHODS
We assigned men with metastatic, hormone-sensitive prostate cancer to receive 
either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface 
area every 3 weeks for six cycles) or ADT alone. The primary objective was to test 
the hypothesis that the median overall survival would be 33.3% longer among 
patients receiving docetaxel added to ADT early during therapy than among pa-
tients receiving ADT alone.
RESULTS
A total of 790 patients (median age, 63 years) underwent randomization. After a 
median follow-up of 28.9 months, the median overall survival was 13.6 months 
longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 
months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 
95% confidence interval [CI], 0.47 to 0.80; P<0.001). The median time to bio-
chemical, symptomatic, or radiographic progression was 20.2 months in the com-
bination group, as compared with 11.7 months in the ADT-alone group (hazard 
ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). The rate of a prostate-specific antigen 
level of less than 0.2 ng per milliliter at 12 months was 27.7% in the combination 
group versus 16.8% in the ADT-alone group (P<0.001). In the combination group, 
the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 
infection with neutropenia was 2.3%, and the rate of grade 3 sensory neuropathy 
and of grade 3 motor neuropathy was 0.5%.
CONCLUSIONS
Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer re-
sulted in significantly longer overall survival than that with ADT alone. (Funded by 
the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.)
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Regressions of metastatic prostate cancer were first documented in the 1940s and were achieved with surgical castra-
tion; subsequently, androgen-deprivation therapy 
(ADT) became the mainstay of therapy.1 Attempts 
to improve the efficacy or decrease the treatment 
burden of ADT have included the use of anti-
androgens alone, intermittent dosing of ADT, 
and the use of an antiandrogen combined with 
medical or surgical castration.2-4 A meta-analysis 
revealed an increase in survival of 3 percentage 
points at 5 years with concurrent use of a non-
steroidal antiandrogen at the time of initiation 
of ADT.2 However, resistance to ADT occurs in 
most patients, with the result that the median 
survival among patients with metastatic prostate 
cancer is approximately 3 years.5,6 In patients 
with resistance to ADT, docetaxel therapy re-
sulted in a median survival that was approxi-
mately 2.5 months longer than that with mito-
xantrone and prednisone.7,8
Prior studies of chemotherapy plus ADT, which 
did not show a benefit, were small studies that 
involved primarily patients with a relatively low 
tumor burden.9,10 Definitions of a high burden of 
disease have included the presence of visceral 
metastases, a bone-metastasis burden categorized 
by site (beyond the axial skeleton) or by a high 
number of lesions, or a combination of these.9,11,12 
In this study, the E3805 study, patients received 
ADT alone or ADT plus docetaxel at the begin-
ning of ADT for metastatic hormone-sensitive 
prostate cancer, and stratification was performed 




The primary objective of the E3805 study was to 
determine whether docetaxel therapy at the be-
ginning of ADT for metastatic hormone-sensitive 
prostate cancer would result in longer overall 
survival than that with ADT alone. The study was 
designed in 2005 by the Eastern Cooperative On-
cology Group (ECOG; now part of ECOG-ACRIN) 
and was approved by the institutional review 
board at each participating institution. The study 
was coordinated by the ECOG-ACRIN Cancer 
Research Group. The ECOG-ACRIN Statistical 
Center collected the data and was the leading 
cooperative group and data coordinating center. 
The first two authors attest that the study was 
conducted and monitored as specified by the 
protocol. The first author wrote the first draft of 
the manuscript, with subsequent contributions 
by all the coauthors. The authors vouch for the 
accuracy and completeness of the data presented. 
The protocol with the statistical analysis plan 
is available with the full text of this article at 
NEJM.org. Sanofi donated the docetaxel for 
early use (i.e., before progression during ADT) 
and provided a grant to ECOG-ACRIN but had 
no role in the design of the protocol, the collec-
tion or analysis of the data, or the preparation of 
the manuscript.
Patients
Patients were enrolled by ECOG-ACRIN, the 
Southwest Oncology Group, the Alliance for 
Clinical Trials in Oncology, and NRG Oncology 
(a merged group that includes the National Sur-
gical Adjuvant Breast and Bowel Project, the Ra-
diation Therapy Oncology Group, and the Gyne-
cologic Oncology Group) and through the Clinical 
Trials Support Unit. Eligible patients had a 
pathological diagnosis of prostate cancer or a 
clinical scenario consistent with prostate cancer 
with an elevated prostate-specific antigen (PSA) 
level; radiologic evidence of metastatic disease; 
and an ECOG performance-status score of 0, 1, 
or 2 (on a scale from 0 to 5, with higher scores 
indicating greater disability; patients with a score 
of 2 were eligible if the decrement in function-
ing was due to prostate cancer). Prior adjuvant 
ADT was allowed if the duration of therapy was 
24 months or less and progression had occurred 
more than 12 months after completion of ther-
apy. Patients who were receiving ADT for meta-
static disease were eligible if there was no evidence 
of progression and treatment had commenced 
within 120 days before randomization. Organ 
function that was adequate for doce taxel treat-
ment was required (details are provided in the 
protocol). All patients provided written informed 
consent in accordance with institutional and 
federal guidelines.
Treatment Plan, Stratification,  
and Randomization
Patients were randomly assigned to ADT alone 
or to combination therapy with ADT plus doce-
taxel at a dose of 75 mg per square meter of 
body-surface area given every 3 weeks for six 
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cycles, with premedication with 8 mg of oral 
dexamethasone at 12 hours, 3 hours, and 1 hour 
before docetaxel infusion. Daily prednisone was 
not required. Patients were stratified according 
to age (<70 years vs. ≥70 years), ECOG perfor-
mance-status score (0 or 1 vs. 2), and planned 
use of combined androgen blockade for more 
than 30 days (yes vs. no) or agents approved for 
prevention of skeletal-related events in castration-
resistant disease (zoledronic acid or denosumab) 
(yes vs. no). Patients were also stratified accord-
ing to the duration of prior adjuvant ADT (<12 
months vs. ≥12 months) and the extent of metas-
tases (high volume [defined as the presence of 
visceral metastases or ≥4 bone lesions with ≥1 
beyond the vertebral bodies and pelvis] vs. low 
volume). Patients were required to take at least 
500 mg of oral calcium carbonate and at least 
400 IU of vitamin D per day.
Dose Modifications
No dose modifications of ADT were allowed, 
and the use of a nonsteroidal antiandrogen with 
castration (medical or surgical) at the time of 
initiation of therapy was at the discretion of the 
investigator. Intermittent hormonal therapy was 
not allowed. For docetaxel, no more than two 
dose modifications (decreases to 65 mg per 
square meter and 55 mg per square meter) were 
allowed. Dose adjustments were made according 
to the organ system that showed the greatest de-
gree of toxic effects, which were graded accord-
ing to the National Cancer Institute (NCI) Com-
mon Terminology Criteria for Adverse Events 
(CTCAE; version 3.0 until September 2011 and 
version 4.0 thereafter). Details on dosing are 
provided in the protocol. If a dose was reduced 
owing to toxic effects, it was not increased sub-
sequently, and docetaxel was discontinued if 
administration was delayed longer than 3 weeks 
from the scheduled day of dosing. The use of 
growth factors was at the discretion of the inves-
tigator.
Monitoring of Toxic Effects and Efficacy
Patients assigned to combination therapy were 
seen every 3 weeks during the period of docetaxel 
administration and then every 3 months. Patients 
assigned to ADT alone were seen every 3 months. 
For the reporting of serious adverse events to the 
NCI and to guide dose modifications, CTCAE 
version 3.0 was used until September 2011, at 
which time the study began using version 4.0. To 
ensure consistency, case-report forms for toxic 
effects that were recorded in the study database 
retained the use of version 3.0. All grade 3 or 
higher toxic effects in the combination group 
were captured, and an attribution of relatedness 
to study therapy was made by the local investiga-
tors. Adverse events among patients assigned to 
ADT alone were not routinely documented, al-
though major adverse events were to be reported.
PSA levels were measured at each scheduled 
visit. Imaging (computed tomography [CT] of 
the abdomen and pelvis, technetium-99m bone 
scanning, and radiography or CT of the chest) 
was performed at baseline and at the time of 
documented castration resistance or as clinically 
indicated. Disease progression on imaging was 
determined according to the Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.013 
(the criteria are summarized in the protocol). A 
complete serologic response was defined as a 
PSA level of less than 0.2 ng per milliliter on two 
consecutive measurements at least 4 weeks apart. 
Serologic progression was defined as an increase 
in the PSA level of more than 50% above the 
nadir reached after the initiation of ADT, with 
two consecutive increases at least 2 weeks apart. 
The date of a first recorded increase of more 
than 50% above the nadir was deemed the date 
of progression. If the nadir level was less than 
2 ng per milliliter, a minimum increase of more 
than 2 ng per milliliter was required.
All time-to-event end points were determined 
from the time of randomization. Overall survival 
was defined as the time until death from any 
cause. The time to castration-resistant prostate 
cancer was defined as the time until document-
ed clinical or serologic progression with a testos-
terone level of less than 50 ng per deciliter (or 
source documentation of medical castration or 
surgical castration). The time to clinical pro-
gression was defined as the time until increas-
ing symptoms of bone metastases; progression 
according to RECIST, version 1.0; or clinical 
deterioration due to cancer according to the in-
vestigator’s opinion.
Statistical Analysis
The study underwent two major amendments 
(details are provided in the protocol); in all ver-
sions, an intention-to-treat analysis plan was 
used. With each amendment, the sample size 
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was adjusted so that the study would have 80% 
power to detect a 33.3% difference in median 
overall survival between the combination group 
and the ADT-alone group, with the use of a 
stratified log-rank test at a one-sided alpha level 
of 2.5%. At study inception, only patients with 
high-volume disease were to be enrolled, and the 
sample size was to be 568 patients. After com-
pletion of enrollment in the NCI-sponsored 
S9346 trial,4 an amendment to the E3805 study 
was made in July 2008, after 53 patients had been 
enrolled, to include patients with low-volume 
disease. A prospective stratification of high vol-
ume versus low volume of metastatic disease 
was added, and the sample size was increased to 
600 patients. The final amendment was made in 
December 2011, after 579 patients had been en-
rolled, to reflect new data documenting an in-
crease in median overall survival owing to the 
use of PSA in the detection and monitoring of 
disease activity5 (initial projections were based 
on studies from the pre-PSA era) and to address 
the September 2011 report of the data and safety 
monitoring committee, which noted that 70% of 
enrolled patients had high-volume disease. The 
final design required the enrollment of 780 pa-
tients, with projections of median overall sur-
vival with ADT alone of 33 months among pa-
tients with high-volume disease and 67 months 
among patients with low-volume disease.
Interim analyses were to be performed before 
all semiannual meetings of the data and safety 
monitoring committee starting when approxi-
mately 25% of the planned full information was 
obtained and continuing until either the criteria 
for early stopping were met or full information 
was obtained (after 399 deaths). The study was 
monitored for early stopping for futility with the 
use of repeated-confidence-interval methods.14 At 
each interim analysis, the nominal (1 − [2 × alpha]) 
confidence interval for the hazard ratio for death 
in the comparison of the combination-therapy 
group with the ADT-alone group was computed. 
For a given analysis time (information fraction), 
alpha was set at the nominal one-sided signifi-
cance level of the use function boundary. Infor-
mation from interim analyses was reviewed by 
members of the independent data and safety 
monitoring committee, who determined wheth-
er efficacy or futility had been demonstrated and 
who decided whether the study should be stopped 
and the results reported early.
Descriptive statistics were used to characterize 
patients at study entry. Kaplan–Meier estimates15 
were used for event-time distributions. Cox pro-
portional-hazard models,16 stratified according 
to the factors described above, were used to esti-
mate hazard ratios for time-to-event end points. 
Stratified log-rank tests17 were used to compare 
event-time distributions between the two groups. 
Response rates were compared with the use of 
Fisher’s exact test.18 An intention-to-treat analy-
sis was conducted that included all randomly 
assigned patients regardless of eligibility and 
treatment status. P values are two-sided, and con-
fidence intervals are at the 95% level.
R esult s
Patients
From July 2006 through December 2012, a total 
of 790 patients were enrolled and underwent ran-
domization. Ten patients were ineligible, 7 had 
incomplete information to assess eligibility, and 
6 patients in the combination group did not 
start the assigned therapy (Fig. S1 in the Supple-
mentary Appendix, available at NEJM.org). All 
randomly assigned patients were followed and 
included in the primary analysis of their assigned 
group. At the planned interim analysis in Octo-
ber 2013, a total of 53% of the planned full in-
formation had been obtained, prespecified crite-
ria for significance had been met, and the data 
were released by the data and safety monitoring 
committee. This report represents data with a 
cutoff date for survival of December 23, 2013; 
the median follow-up was 28.9 months, with 
136 deaths in the ADT-alone group and 101 
deaths in the combination group. All other data 
reflect the database as of December 23, 2014.
Patient characteristics were well balanced be-
tween the two groups (Table 1). The median age 
was 64 years (range, 36 to 88) in the combina-
tion group and 63 years (range, 39 to 91) in the 
ADT-alone group. In both groups, approximately 
85% of the patients were white, approximately 
70% had an ECOG performance-status score of 0, 
approximately 65% had high-volume disease, and 
approximately 60% had a Gleason score of 8 or 
higher (on a scale from 2 to 10, with higher 
scores indicating a more aggressive form of pros-
tate cancer and a worse prognosis). In both 
groups, 73% of the patients had received no 
prior local therapy for prostate cancer with cura-
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Characteristic







Race — no. (%)†
White 344 (86.6) 330 (84.0)
Black 39 (9.8) 37 (9.4)
Other  4 (1.0)  6 (1.5)
Unknown 10 (2.5) 20 (5.1)
ECOG performance status — no. (%)‡
0 277 (69.8) 272 (69.2)
1 114 (28.7) 115 (29.3)
2  6 (1.5)  6 (1.5)
Volume of metastases — no. (%)§
Low 134 (33.8) 143 (36.4)
High 263 (66.2) 250 (63.6)
Visceral metastases — no. (%)  57 (14.4)  66 (16.8)
Gleason score — no. (%)¶
4–6 21 (5.3) 21 (5.3)
7  96 (24.2)  83 (21.1)
8–10 241 (60.7) 243 (61.8)
Unknown 39 (9.8)  46 (11.7)
PSA level at start of ADT — ng/ml
Median 50.9 52.1
Range 0.2–8540.1 0.1–8056.0
Prior treatment for prostate cancer — no. (%)
No local therapy 289 (72.8) 286 (72.8)
Primary radiation 27 (6.8) 33 (8.4)
Prostatectomy  81 (20.4)  73 (18.6)
Missing data 0  1 (0.3)
Adjuvant ADT — no. (%) 18 (4.5) 16 (4.1)
Time from start of ADT to randomization — mo‖
Median 1.2 1.3
Range 0.03–3.9 0.03–3.9
No ADT before randomization — no. (%)  51 (12.8)  52 (13.2)
*  There were no significant differences in characteristics between the two groups when analyzed with the use of the 
Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables, with the categories for 
“unknown” or “missing data” excluded. ADT denotes androgen-deprivation therapy, and PSA prostate-specific antigen.
†  Race was self-reported.
‡  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicat-
ing greater disability. One patient assigned to ADT alone did not have an on-study form submitted, so the ECOG per-
formance-status score was unknown, but the stratification by the site placed the patient into the stratum of a perfor-
mance-status score of 2 at randomization.
§  A high volume of metastases was defined by the presence of visceral metastases or four or more bone lesions with at 
least one beyond the vertebral bodies and pelvis. One patient assigned to ADT alone did not have an on-study form 
submitted, so the volume of metastases was unknown, but the stratification by the site placed the patient into the high-
volume stratum at randomization.
¶  Gleason scores range from 2 to 10, with higher scores indicating a more aggressive form of prostate cancer and a 
worse prognosis.
‖  Time from start of ADT to randomization is among patients who started ADT before randomization.
Table 1. Baseline Characteristics of the Patients.*
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tive (rather than palliative) intent. Among pa-
tients who started ADT before randomization, 
the median time from the start of ADT to ran-
domization was 1.2 months (range, 0 to 3.9) in 
the combination group and 1.3 months (range, 
0 to 3.9) in the ADT-alone group.
Survival
The median overall survival was 13.6 months 
longer with the addition to ADT of early docetax-
el than with ADT alone (57.6 months vs. 44.0 
months; hazard ratio for death in the combina-
tion group, 0.61; 95% confidence interval [CI], 
0.47 to 0.80; P<0.001) (Fig. 1A). There were 85 
prostate-cancer deaths in the combination group 
and 114 prostate-cancer deaths in the ADT-alone 
group (Table S1 in the Supplementary Appen-
dix). The benefit at the last analysis was more 
apparent in the subgroup with high-volume dis-
ease than in the overall study population 
(Fig. 1B), with a median overall survival that was 
17.0 months longer in the combination group 
than in the ADT-alone group (49.2 months vs. 
32.2 months; hazard ratio for death, 0.60; 95% 
CI, 0.45 to 0.81; P<0.001). The median survival 
at the time of the analysis had not been reached 
in the subgroup with low-volume disease in ei-
ther study group (Fig. 1C). A benefit of docetax-
el treatment was detected in all the subgroups 
analyzed (Fig. 2).
Secondary End Points and Toxic Effects
The proportion of patients who had a decrease 
in the PSA level to less than 0.2 ng per milliliter 
at 12 months was 27.7% in the combination 
group, as compared with 16.8% in the ADT-
alone group (P<0.001) (Table 2). The median 
time to the development of castration-resistant 
prostate cancer (biochemical, symptomatic, or 
radiographic) was 20.2 months with combina-
tion therapy, as compared with 11.7 months 
with ADT alone (hazard ratio in the combina-
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Figure 1. Kaplan–Meier Estimates of Overall Survival.
The median duration of follow-up was 28.9 months 
among all patients (Panel A), 29.2 months among pa-
tients with high-volume disease (Panel B), and 27.6 
months among patients with low-volume disease (Pan-
el C). ADT denotes androgen-deprivation therapy, and 
NR not reached.
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(Table 2, and Fig. S2A in the Supplementary 
Appendix). The median time to clinical progres-
sion was 33.0 months with combination therapy, 
as compared with 19.8 months with ADT alone 
(hazard ratio, 0.61; 95% CI, 0.50 to 0.75; P<0.001) 
(Table 2, and Fig. S2B in the Supplementary Ap-
pendix).
Among the patients who received combina-
tion therapy, approximately 2% had a treatment-
related grade 3 or 4 allergic reaction; grade 3 
fatigue occurred in 4% of the patients, and 
grade 3 diarrhea, stomatitis, motor neuropathy, 
and sensory neuropathy each occurred at a rate 
of 1% or less (Table 3). Approximately 1% of the 
patients in the combination group had a throm-
boembolic event. One patient died suddenly at 
home of an unknown cause during the course of 
docetaxel therapy; the death was considered to 
be possibly related to docetaxel according to the 
Adverse Event Expedited Reporting System. Ap-
proximately 6% of the patients in the combina-
tion group had neutropenic fever, and approxi-
mately 2% had grade 3 or 4 infection with 
neutropenia.
Figure 2. Hazard Ratios for Death in Subgroups.
Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indi-
cating greater disability. Patients were stratified on the basis of an ECOG performance-status score of 0 or 1 versus 
2, but because there were so few patients with a score of 2, the analysis was performed on the basis of a score of 0 
versus 1 or 2. Race was self-reported; other or unknown race includes black (76 patients), Asian (8), Native Ameri-
can (2), and unknown (30). A high volume of metastases was defined by the presence of visceral metastases or four 
or more bone lesions with at least one beyond the vertebral bodies and pelvis. Gleason scores range from 2 to 10, 
with higher scores indicating a more aggressive form of prostate cancer and a worse prognosis. The x axis of the 
forest plot is scaled according to the natural logarithm of the hazard ratio. The size of the squares is proportional to 
the inverse of the variance of the log hazard ratio (small squares correspond to large variances).
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Assigned Therapy Administered  
and Subsequent Therapy
Approximately 86% of the 390 patients in the 
combination group who started the assigned 
therapy completed six cycles of docetaxel therapy 
(Table S2 in the Supplementary Appendix), and 
approximately 74% of all the treated patients 
received all planned cycles without dose modifi-
cations. At the time of this analysis, castration-
resistant prostate cancer with at least biochemi-
cal progression had developed in 287 patients 
assigned to ADT alone; 137 patients of these 
patients had received docetaxel for castration-
resistant prostate cancer, and another 10 patients 
had received docetaxel before castration resis-
tance was confirmed. In addition, 104 patients 
had received abiraterone or enzalutamide after 
confirmed castration resistance (9 of these pa-
tients may have received placebo as part of a 
trial). Table S3 in the Supplementary Appendix 
documents the use of other therapies that have 
been shown to prolong overall survival in patients 
with castration-resistant prostate cancer.
Discussion
Improvements in outcomes in men with meta-
static castration-resistant prostate cancer have 
been achieved with the use of cytotoxic chemo-
therapy, next-generation hormonal therapies, 
immunotherapy, and therapy with radiopharma-
ceutical agents.19-25 This study showed that 
End Point
ADT plus Docetaxel 
(N = 397)
ADT Alone 
(N = 393) P Value
Hazard Ratio 
(95% CI)
PSA level <0.2 ng/ml at 6 mo — no. (%) 127 (32.0) 77 (19.6) <0.001
PSA level <0.2 ng/ml at 12 mo — no. (%) 110 (27.7) 66 (16.8) <0.001
Time to castration-resistant prostate cancer — mo*
Median 20.2 11.7 <0.001 0.61 (0.51–0.72)
95% CI 17.2–23.6 10.8–14.7
Time to clinical progression — mo†
Median 33.0 19.8 <0.001 0.61 (0.50–0.75)
95% CI 27.3–41.2 17.9–22.8
*  The time to castration-resistant prostate cancer was the time until documented clinical or serologic progression with a testosterone level of 
less than 50 ng per deciliter (or source documentation of medical castration or surgical castration).
†  Clinical progression was defined by increasing symptoms of bone metastases; progression according to the Response Evaluation Criteria in 
Solid Tumors, version 1.0; or clinical deterioration due to cancer according to the investigator’s opinion.
Table 2. Secondary End Points.
Event Grade 3 Grade 4 Grade 5
no. of patients (%)
Allergic reaction  7 (1.8) 1 (0.3) 0
Fatigue 16 (4.1) 0 0
Diarrhea  4 (1.0) 0 0
Stomatitis  2 (0.5) 0 0
Neuropathy, motor  2 (0.5) 0 0
Neuropathy, sensory  2 (0.5) 0 0
Thromboembolism  1 (0.3) 2 (0.5) 0
Sudden death 0 0 1 (0.3)
Anemia  4 (1.0) 1 (0.3) 0
Thrombocytopenia 0 1 (0.3) 0
Neutropenia 12 (3.1) 35 (9.0) 0
Febrile neutropenia 15 (3.8) 9 (2.3) 0
Infection with neutropenia  5 (1.3) 4 (1.0) 0
Any event  65 (16.7) 49 (12.6) 1 (0.3)
*  Patients were classified according to the worst grade reported across all body 
systems. Patients assigned to ADT plus docetaxel were monitored every 3 
weeks during the time docetaxel was administered and then every 3 months, 
whereas patients assigned to the ADT-alone group were seen every 3 months 
after randomization. Toxic effects in the group that received ADT plus 
docetaxel were captured at this frequency to ascertain the adverse-event pro-
file of chemotherapy. The adverse-event profile of ADT was assumed to be 
common to the two groups. The potential risk of ascertainment bias for ad-
verse events and early progression in the ADT-plus-docetaxel group was rec-
ognized, but such bias, if it existed, would have favored the ADT-alone group.
Table 3. Adverse Events of Grade 3 or Higher among the 390 Patients Who 
Received the Docetaxel-Containing Regimen and Had Follow-up Data 
Available.*
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on September 3, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;8 nejm.org August 20, 2015 745
Chemohormonal Ther apy in Prostate Cancer
docetaxel given at the time ADT was initiated for 
hormone-sensitive disease resulted in better can-
cer control than that with ADT alone, with a 
longer time to the development of castration resis-
tance, a higher rate of decrease of the PSA level 
to less than 0.2 ng per milliliter at 12 months, a 
lower number of prostate-cancer deaths, and 
substantially longer overall survival. The longer 
overall survival than that with ADT alone was 
achieved despite the fact that almost half the 287 
patients who received ADT alone and then met 
the criteria for castration resistance received 
docetaxel at the time of disease progression 
along with other therapies that prolong overall 
survival in patients with metastatic castration-
resistant prostate cancer.
The definition of high-volume disease used 
for this protocol was a combination of features 
from prior classifications. All the definitions 
included the presence of nonnodal, soft-tissue 
visceral disease as a predictor of poor prognosis. 
This protocol made use of sites of bone metas-
tases and the number of metastases to avoid 
classifying patients with three or fewer sites as 
having high-volume disease even if one lesion 
was beyond the vertebrae and pelvis (any lesion 
beyond the vertebrae and pelvis, irrespective of 
total lesion count, would be classified as “exten-
sive” according to the definition of the South-
west Oncology Group4). In the subgroup of pa-
tients with high-volume disease, the median 
overall survival was 17.0 months longer in the 
combination group than in the ADT-alone group 
(49.2 months vs. 32.2 months). On the basis of 
an unpublished analysis of data from the S9346 
trial5 we had projected a median survival of 
33 months among patients with high-volume 
disease (according to the definition used in our 
protocol) in the ADT-alone group, and as such, 
the definition was reproducible across two phase 
3 studies conducted in a similar time period.
A previously reported randomized study in-
volving 380 patients (the GETUG-AFU 15 study), 
which had a similar design to that of the current 
study, did not detect longer overall survival with 
combination therapy.10 The median overall sur-
vival was longer than in our study — 54.2 months 
with ADT alone (which suggests that the study 
had a different case mix than that in our study) 
— and was first analyzed in 2011, before there 
was widespread access to newer therapies that 
have been shown to prolong overall survival 
among patients with castration-resistant pros-
tate cancer. In the GETUG-AFU 15 study, the 
time to progression was longer, the number of 
prostate-cancer deaths was smaller, and the num-
ber of treatment-related deaths was larger (4 of 
195 patients) with early docetaxel therapy than 
with ADT alone. The Medical Research Council 
STAMPEDE trial will add further data on the 
role of docetaxel in hormone-sensitive prostate 
cancer; to date, the overall survival in the ADT-
alone group in that study is 42 months,26 a find-
ing similar to that in our study.
In conclusion, the combination of standard 
ADT and six cycles of docetaxel resulted in sig-
nificantly longer overall survival than that with 
standard ADT alone in men with hormone-sensi-
tive metastatic prostate cancer. The clinical 
benefit at this early analysis was more pro-
nounced among patients with a higher burden of 
disease.
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